This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kuriyama, M. Articles by Chu, T. M. Search for Related Content PubMed PubMed Citation Articles by Kuriyama, M. Articles by Chu, T. M.

Use of Human Prostate-specific Antigen in Monitoring Prostate Cancer¹

Department of Diagnostic Immunology Research and Biochemistry [M. K., M. C. W., C. L. L., L. D. P., C. S. K., H. I., T. M. C.] and the National Prostatic Cancer Project [N. H. S., G. P. M.], Roswell Park Memorial Institute, ^,3 Buffalo, New York 14263, and Department of Urology, Gifu University School of Medicine, Gifu 500, Japan [T. N.]

The newly reported human prostate-specific antigen (PA) is a specific histiotypic product of human prostate. With the use of a sensitive enzyme immunoassay, the circulating PA in prostatic cancer patients has been evaluated clinically. In 96 patients with advanced stage of disease (D₂) and receiving chemotherapies, the pretreatment serum PA levels were found to be of prognostic value with regard to the patient survival. Ten patients with metastatic prostate cancer were monitored for more than 32 weeks by 183 serial PA values and were found generally to respond to the treatment. Additionally, in another group of 32 patients who underwent curative therapies for localized prostate cancer, 161 serum samples were evaluated during periods of 12 to 114 weeks (average 56 weeks). Of these patients, five developed metastases during follow-up, and all were shown to exhibit increasingly elevated PA values, either corresponding to or prceding the clinical diagnosis of disease recurrence. These results suggest that PA is a new marker with potential value to merit further clinical study.

¹ This work was supported in part by CA-15126 and CA-15437, awarded by the National Cancer Institute, NIH, Department of Health & Human Services.

² To whom requests for reprints should be addressed.

³ Investigators are: Dr. S. A. Leoning, University of Iowa Hospitals and Clinics; Dr. R. P. Gibbons, The Mason Clinic; Dr. G. R. Prout, Massachusetts General Hospital; Dr. W. W. Scott, Johns Hopkins Hospital; Dr. M. Soloway, University of Tennessee; Dr. J. D. Schmidt, University of California at San Diego; Dr. S. Bergman, Tulane Medical Center; Dr. J. E. Pontes and Dr. J. M. Pierce, Hutzel Hospital/Wayne State University; Dr. P. Scardino, Baylor University; Dr. D. McLeod, Walter Reed Army Medical Center; Dr. C. McKiel, Rush-Presbyterian/St. Luke's Medical Center; Dr. J. deKernion, University of California at Los Angeles; and Dr. S. Beckley, Roswell Park Memorial Institute.

Received 1/26/81. Accepted 6/30/81.

This article has been cited by other articles:

				D. Floryk, S. L. Tollaksen, C. S. Giometti, and E. Huberman Differentiation of Human Prostate Cancer PC-3 Cells Induced by Inhibitors of Inosine 5'-Monophosphate Dehydrogenase Cancer Res., December 15, 2004; 64(24): 9049 - 9056. [Abstract] [Full Text] [PDF]

				S. P. Balk, Y.-J. Ko, and G. J. Bubley Biology of Prostate-Specific Antigen J. Clin. Oncol., January 15, 2003; 21(2): 383 - 391. [Abstract] [Full Text] [PDF]

				C. Lopez-Otin and E. P. Diamandis Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features Endocr. Rev., August 1, 1998; 19(4): 365 - 396. [Abstract] [Full Text] [PDF]